The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies

Autor: Potter, R., Tanderup, K., Kirisits, C., Leeuw, A. de, Kirchheiner, K., Nout, R., Tan, L.T., Haie-Meder, C., Mahantshetty, U., Segedin, B., Hoskin, P., Bruheim, K., Rai, B., Huang, F., Limbergen, E. van, Schmid, M., Nesvacil, N., Sturdza, A., Fokdal, L., Jensen, N.B.K., Georg, D., Assenholt, M., Seppenwoolde, Y., Nomden, C., Fortin, I., Chopra, S., Heide, U. van der, Rumpold, T., Lindegaard, J.C., Jurgenliemk-Schulz, I., Dumas, I., Chargari, C., Swamidas, J., Shrivastava, S.K., Lowe, G., Hudej, R., Hellebust, T.P., Menon, G., Oinam, A.S., Cooper, R., Bownes, P., Banasik, E.V., Sundset, M., Pieters, B., Lutgens, L.C.H.W., Villafranca, E., Hadjiev, J., Bachand, F., Erickson, B., Jacobson, G., Anttila, M., EMBRACE Collaborative Grp
Rok vydání: 2018
Předmět:
medicine.medical_specialty
STANDARDIZED UPTAKE VALUE
MODULATED RADIATION-THERAPY
medicine.medical_treatment
Brachytherapy
R895-920
Translational research
LATE RECTAL TOXICITY
Article
030218 nuclear medicine & medical imaging
Medical physics. Medical radiology. Nuclear medicine
03 medical and health sciences
0302 clinical medicine
SDG 3 - Good Health and Well-being
RATE INTRACAVITARY BRACHYTHERAPY
Cervix cancer
QUALITY-OF-LIFE
CARBON ION RADIOTHERAPY
ADVANCED CERVICAL-CANCER
Medicine
Radiology
Nuclear Medicine and imaging

Medical physics
External beam radiotherapy
Medical prescription
RC254-282
ComputingMethodologies_COMPUTERGRAPHICS
DOSE-VOLUME PARAMETERS
Image-guided radiation therapy
Cervical cancer
Contouring
Manchester Cancer Research Centre
business.industry
ResearchInstitutes_Networks_Beacons/mcrc
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
GUIDED ADAPTIVE BRACHYTHERAPY
MRI guided radiotherapy
medicine.disease
3. Good health
Adaptive radiotherapy
Oncology
EXTERNAL-BEAM RADIOTHERAPY
Local control
030220 oncology & carcinogenesis
Observational study
Morbidity
business
Zdroj: EMBRACE Collaborative Group 2018, ' The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies ', Clinical and Translational Radiation Oncology, vol. 9, pp. 48-60 . https://doi.org/10.1016/j.ctro.2018.01.001
Clinical and Translational Radiation Oncology, Vol 9, Iss C, Pp 48-60 (2018)
EMBRACE Collaborative Group 2018, ' The EMBRACE II study : The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies ', Clinical and translational radiation oncology, vol. 9, pp. 48-60 . https://doi.org/10.1016/j.ctro.2018.01.001
Clinical and Translational Radiation Oncology
ISSN: 2405-6308
DOI: 10.1016/j.ctro.2018.01.001
Popis: Graphical abstract
Highlights • Image guided adaptive brachytherapy (IGABT) is changing clinical practice. • The EMBRACE studies benchmark IGABT in cervix cancer. • A multi-parametric dose prescription protocol is being validated in EMBRACE II. • EMBRACE II is hypothesised to improve outcome: disease, morbidity, quality of life.
The publication of the GEC-ESTRO recommendations one decade ago was a significant step forward for reaching international consensus on adaptive target definition and dose reporting in image guided adaptive brachytherapy (IGABT) in locally advanced cervical cancer. Since then, IGABT has been spreading, particularly in Europe, North America and Asia, and the guidelines have proved their broad acceptance and applicability in clinical practice. However, a unified approach to volume contouring and reporting does not imply a unified administration of treatment, and currently both external beam radiotherapy (EBRT) and IGABT are delivered using a large variety of techniques and prescription/fractionation schedules. With IGABT, local control is excellent in limited and well-responding tumours. The major challenges are currently loco-regional control in advanced tumours, treatment-related morbidity, and distant metastatic disease. Emerging evidence from the RetroEMBRACE and EMBRACE I studies has demonstrated that clinical outcome is related to dose prescription and technique. The next logical step is to demonstrate excellent clinical outcome with the most advanced EBRT and brachytherapy techniques based on an evidence-based prospective dose and volume prescription protocol. The EMBRACE II study is an interventional and observational multicentre study which aims to benchmark a high level of local, nodal and systemic control while limiting morbidity, using state of the art treatment including an advanced target volume selection and contouring protocol for EBRT and brachytherapy, a multi-parametric brachytherapy dose prescription protocol (clinical validation of dose constraints), and use of advanced EBRT (IMRT and IGRT) and brachytherapy (IC/IS) techniques (clinical validation). The study also incorporates translational research including imaging and tissue biomarkers.
Databáze: OpenAIRE